# Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

> **NCT00113204** · PHASE1 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IPI-504

## Key facts

- **NCT ID:** NCT00113204
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2008-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113204, "Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00113204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*